berberine and estrogen positive breast cancer

Release time ：Dec-13,2024

The relationship between berberine and estrogen receptor-positive (ER+) breast cancer is intricate. Berberine, a naturally occurring compound, possesses anti-inflammatory and antioxidant properties, whereas ER+ breast cancer is characterized by the presence of estrogen receptors on the surface of tumor cells that respond to estrogen.

Research indicates that berberine could influence ER+ breast cancer through various mechanisms. Initially, it inhibits tumor cell proliferation, induces cell cycle arrest, and promotes apoptosis. Additionally, it diminishes the migration and invasiveness of tumor cells, thus curbing tumor metastasis. Furthermore, berberine may modulate the immune system to bolster the body's capacity to eliminate tumor cells.

It is important to acknowledge that while berberine has demonstrated potential therapeutic effects on ER+ breast cancer in laboratory settings, its efficacy and safety in clinical practice require further investigation. Consequently, patients with ER+ breast cancer should adhere to standardized treatment protocols under medical supervision and avoid the indiscriminate use of berberine or any other medication. Moreover, maintaining healthy lifestyle practices, including a balanced diet, regular exercise, and abstaining from smoking and alcohol, can contribute to improved therapeutic outcomes and overall quality of life.